Lilly(US:LLY) Hua Er Jie Jian Wen·2025-12-02 13:47Core Viewpoint - Bank of America raised the target price for Eli Lilly from $950 to $1,286, indicating a 22% upside potential, while reiterating a buy rating due to the company's strong drug pipeline and leading position in obesity and diabetes medications [1] Group 1: New Drug Development Progress - The key catalyst for the target price increase is the faster-than-expected progress in Eli Lilly's new drug pipeline, with the oral GLP-1 drug orforglipron expected to launch in early 2026 instead of late 2026 [3][4] - Eli Lilly is set to accelerate the launch of the highly anticipated oral GLP-1 drug orforglipron, which has received one of the first priority review vouchers from the FDA, with a projected launch date of March 2026 [4] Group 2: Market Leadership in GLP-1 Drugs - Eli Lilly's obesity and diabetes treatment drugs, Zepbound and Mounjaro, maintain a leading position in the competitive GLP-1 drug market, which is crucial for the company's long-term growth [5] - The GLP-1 drug market is large and rapidly growing, with Eli Lilly solidifying its competitive position through its market share in these products, supporting Bank of America's bullish stance [5] Group 3: Industry Valuation Support - The overall increase in the valuation of the large-cap biopharmaceutical sector provides additional support for Eli Lilly's stock price [6] - As the healthcare policy priorities of the Trump administration become clearer, the market is re-embracing the biopharmaceutical sector, which has helped alleviate investor concerns regarding regulatory uncertainties in the pharmaceutical industry [6]